Consequently, pharmacological reagents could be developed to reduce IRF5 or increase IRF4 expression in microglia after stroke, so that the pro-inflammatory response can be prevented and the anti-inflammatory response trigger earlier to clear the ischemic detriment and boost the tissue repair. Here, IRF5 is linked to stroke disorder.